Carfilzomib versus bortezomib: no longer an ENDEAVOR.
| Autor: | van de Donk NW; Department of Hematology, VU University Medical Center, 1081HV Amsterdam, Netherlands. Electronic address: n.vandedonk@vumc.nl. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Lancet. Oncology [Lancet Oncol] 2017 Oct; Vol. 18 (10), pp. 1288-1290. Date of Electronic Publication: 2017 Aug 23. |
| DOI: | 10.1016/S1470-2045(17)30613-7 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|